Tropism-modification strategies for targeted gene delivery using adenoviral vectors

Coughlan, Lynda, Alba, Raul, Parker, Alan L. ORCID: https://orcid.org/0000-0002-9302-1761, Bradshaw, Angela C., McNeish, Iain A., Nicklin, Stuart A. and Baker, Andrew H. 2010. Tropism-modification strategies for targeted gene delivery using adenoviral vectors. Viruses 2 (10) , pp. 2290-2355. 10.3390/v2102290

Preview

PDF - Published Version Available under License Creative Commons Attribution. Download (2MB) | Preview

Abstract

Achieving high efficiency, targeted gene delivery with adenoviral vectors is a long-standing goal in the field of clinical gene therapy. To achieve this, platform vectors must combine efficient retargeting strategies with detargeting modifications to ablate native receptor binding (i.e. CAR/integrins/heparan sulfate proteoglycans) and “bridging” interactions. “Bridging” interactions refer to coagulation factor binding, namely coagulation factor X (FX), which bridges hepatocyte transduction in vivo through engagement with surface expressed heparan sulfate proteoglycans (HSPGs). These interactions can contribute to the off-target sequestration of Ad5 in the liver and its characteristic dose-limiting hepatotoxicity, thereby significantly limiting the in vivo targeting efficiency and clinical potential of Ad5-based therapeutics. To date, various approaches to retargeting adenoviruses (Ad) have been described. These include genetic modification strategies to incorporate peptide ligands (within fiber knob domain, fiber shaft, penton base, pIX or hexon), pseudotyping of capsid proteins to include whole fiber substitutions or fiber knob chimeras, pseudotyping with non-human Ad species or with capsid proteins derived from other viral families, hexon hypervariable region (HVR) substitutions and adapter-based conjugation/crosslinking of scFv, growth factors or monoclonal antibodies directed against surface-expressed target antigens. In order to maximize retargeting, strategies which permit detargeting from undesirable interactions between the Ad capsid and components of the circulatory system (e.g. coagulation factors, erythrocytes, pre-existing neutralizing antibodies), can be employed simultaneously. Detargeting can be achieved by genetic ablation of native receptor-binding determinants, ablation of “bridging interactions” such as those which occur between the hexon of Ad5 and coagulation factor X (FX), or alternatively, through the use of polymer-coated “stealth” vectors which avoid these interactions. Simultaneous retargeting and detargeting can be achieved by combining multiple genetic and/or chemical modifications.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Subjects:	Q Science > QH Natural history > QH426 Genetics Q Science > QR Microbiology > QR355 Virology R Medicine > RM Therapeutics. Pharmacology
Uncontrolled Keywords:	adenovirus; retargeting; detargeting; tropism; ligand; capsid protein
Additional Information:	Pdf uploaded in accordance with publisher's policy at http://www.sherpa.ac.uk/romeo/issn/1999-4915/ (accessed 20/02/2014).
Publisher:	MDPI AG
ISSN:	1999-4915
Date of First Compliant Deposit:	30 March 2016
Last Modified:	13 May 2023 16:43
URI:	https://orca.cardiff.ac.uk/id/eprint/43276

Citation Data

Cited 89 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item